RealVNC Licenses Remote Access Technology to Beckman Coulter
News Jan 19, 2015
Beckman Coulter and RealVNC™ today announced that Beckman Coulter will be licensing RealVNC’s technology for its support systems.
VNC enables a computer user to remotely access another computer or device in a secure and reliable manner. Beckman Coulter will be deploying RealVNC’s top end solution, VNC with an Enterprise license to its life sciences and diagnostics products to enable it to efficiently support these systems. In addition the company will also use RealVNC’s VNC Viewer SDK to create its own Viewer for iOS, which will enable its technical support representatives to take control of their systems remotely from an iPad or iPhone, enabling reps the flexibility to use the technology in the field and onsite.
VNC is used widely across every industry sector for many applications. With cross-platform support for the widest range of operating systems, including Windows, Mac and UNIX. VNC can be licensed in three ways as Enterprise, Personal and Free to suit individual requirements. The software comprises a VNC Server application on the machine to be controlled and a VNC Viewer component on the controlling machine. With no agents or centralized servers required, VNC enables trouble-free installation and use.
“RealVNC’s technology and expertise will allow us to enhance our products and the way we serve our laboratory customers,” said John Hetzler, Software Engineering Senior Manager, Workflow and IT Solutions for Beckman Coulter Diagnostics. “The collaboration with RealVNC will enable us to develop customized technology that will enhance our IT solutions.”
“This is yet another great example of a large organization leveraging the power of VNC as part of a range of commercially available devices, worldwide,” said Richard Pickul, Strategic Alliances Manager, RealVNC. “We are delighted to be working with Beckman Coulter to deliver remote access capabilities to their life sciences and diagnostics products and continue to look forward to expanding the relationship in the future.”
Artificial intelligence is having a positive impact on drug development and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling.READ MORE